New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …

Simple Summary Multiple Myeloma (MM) is a hematologic malignancy caused by aberrant
plasma cell proliferation in the bone marrow (BM) and constitutes the second most common …

The historical lack of preclinical models reflecting the genetic heterogeneity of multiple
myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this …

Background Pomalidomide and dexamethasone is a standard of care for patients with
multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE …

Oncology drug development has benefited from the ability in many cases to directly measure
disease burden by clinical and radiographic measures. Tumor-based end points including …

Abstract Anti-PD-1/PD-L1 inhibitors provide a survival advantage over conventional
therapies for treatment of advanced or metastatic cancer. However, the factors determining …

Avoiding immune destruction is a hallmark of cancer. Over the past few years, significant
advances have been made in understanding immune dysfunction and immunosuppression …

Despite considerable advances in treatment approaches in the past two decades, multiple
myeloma remains an incurable disease. Treatments for myeloma continue to evolve with …

Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …

Teclistamab, a B-cell maturation antigen (BCMA)-and CD3–targeting bispecific antibody, is
an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy …